MedTrace Logo

Supplementation With Omega-3: Mechanism of Action

NCT02036307 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-03-01

No results posted yet for this study

Summary

This is a trial of two marketed fish oil supplements, one with a high EPA:DHA ratio and the other with a high DHA:EPA ratio, to examine differential effects on platelet function, blood pressure, and fasting triglyceride levels.

Conditions

  • Hypertriglyceridemia

Interventions

DIETARY_SUPPLEMENT

DHA-enriched

DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks

DIETARY_SUPPLEMENT

EPA-enriched

EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Dhananjay Vaidya · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-05-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02036307 on ClinicalTrials.gov